

CEO Hanna Sjöström on Clinical and Strategic Milestones – Redeye Interview Q1 2025

Following a strengthened shareholder base and the first baby enrolled in Neola Medical's Swedish clinical pilot study, CEO Hanna Sjöström joins Redeye to discuss recent milestones and what lies ahead.

She shares insights into the company's clinical progress, recent international patent grants, and the path toward U.S. market readiness, including upcoming plans for the pivotal clinical study and key strategic considerations around manufacturing.

Watch the full interview here: [*Redeye Interview with CEO Hanna Sjöström following Neola Medical's Q1 2025 report*](#)

Access the interview and additional insights from Redeye here: <https://www.redeye.se/company/neola-medical>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Image Attachments

[Redeye Interview Q1 2025](#)

Attachments

[CEO Hanna Sjöström on Clinical and Strategic Milestones – Redeye Interview Q1 2025](#)